Genelux (NASDAQ:GNLX – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Genelux and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -125.58% | -86.03% |
| Bullfrog AI | N/A | -131.39% | -114.76% |
Insider and Institutional Ownership
37.3% of Genelux shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 0 | 0 | 4 | 0 | 3.00 |
| Bullfrog AI | 0 | 0 | 0 | 0 | N/A |
Genelux presently has a consensus target price of $32.33, indicating a potential upside of 1,403.88%. Given Genelux’s higher possible upside, analysts clearly believe Genelux is more favorable than Bullfrog AI.
Risk and Volatility
Genelux has a beta of -1.37, indicating that its share price is 237% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Valuation and Earnings
This table compares Genelux and Bullfrog AI’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genelux | $170,000.00 | 434.43 | -$28.30 million | ($0.97) | -2.22 |
| Bullfrog AI | $60,000.00 | 226.34 | -$5.36 million | ($0.88) | -1.97 |
Bullfrog AI has lower revenue, but higher earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Summary
Genelux beats Bullfrog AI on 8 of the 12 factors compared between the two stocks.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
